Stock listing
GPH Stock Price, News, Filings & Events — Galmed Pharmaceuticals Ltd.
Selected listing: GPH · FWB · EUR · DE
This page tracks Galmed Pharmaceuticals Ltd.'s GPH:FWB listing on FWB in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following GPH:FWB. GPH:FWB is the stock-level entry point for investors researching Galmed Pharmaceuticals Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Galmed Pharmaceuticals Ltd. (Ticker: GLMD) is a public company operating in the American market. The company has a market capitalization of approximately $4.24 million. Galmed focuses on developing innovative therapies for liver diseases and other metabolic disorders.

- Ticker
- GPH:FWB
- Asset type
- Stock
- Market cap
- $5.1M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- FWB
- Currency
- EUR
Galmed Pharmaceuticals Ltd. GPH:FWB stock context
This page tracks Galmed Pharmaceuticals Ltd.'s GPH:FWB listing on FWB in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following GPH:FWB. GPH:FWB is the stock-level entry point for investors researching Galmed Pharmaceuticals Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Galmed Pharmaceuticals Ltd. (Ticker: GLMD) is a public company operating in the American market. The company has a market capitalization of approximately $4.24 million. Galmed focuses on developing innovative therapies for liver diseases and other metabolic disorders.
Research Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. investor report
Review AI stock analysis and investor report context for GPH:FWB.
Galmed Pharmaceuticals Ltd. company profile
View the public company page for Galmed Pharmaceuticals Ltd. on 6ix.
Galmed Pharmaceuticals Ltd. news
Read company news and market updates connected to Galmed Pharmaceuticals Ltd..
Galmed Pharmaceuticals Ltd. investor events
Find investor webinars, events, and replay context for Galmed Pharmaceuticals Ltd..
Alternate listings
GLMD:NASDAQ
US · USD
Alternate listing for Galmed Pharmaceuticals Ltd.; the primary context on this page is GPH:FWB.
GLMD:BOATS
US · USD
Alternate listing for Galmed Pharmaceuticals Ltd.; the primary context on this page is GPH:FWB.
A1XFUX:LS
DE · EUR
Alternate listing for Galmed Pharmaceuticals Ltd.; the primary context on this page is GPH:FWB.
A1XFUX:LSX
DE · EUR
Alternate listing for Galmed Pharmaceuticals Ltd.; the primary context on this page is GPH:FWB.